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Abstract
The influence of the calcium channel blocker verapamil on the sensitivity of mouse fibrosarcoma cells of the line EMT-6
 .  .  .to treatment with Photofrin II PII or tetra 4-sulfonatophenyl porphine TPPS and light has been assessed. Cells were4
treated with 1.5 mgrml PII or 75 mgrml TPPS overnight in the absence or presence of 50 mgrml verapamil and4
subsequently exposed to light. Verapamil increased the sensitivity of the EMT-6 cells to PII-induced photoinactivation by a
factor of 2. In contrast, verapamil decreased the sensitivity of the cells to TPPS -induced photoinactivation by 50–60%.4
Both sensitizers were found to be located to a large extent in lysosomes as revealed by fluorescence microscopy and by
photochemical inactivation of the lysosomal marker enzyme b-N-acetyl-D-glucosaminidase. Verapamil increased the uptake
of PII by 30% and reduced the uptake of TPPS by 20%. Furthermore, verapamil enhanced the binding and uptake of LDL4
by about 40%. In conclusion, the effects of verapamil-induced sensitization of EMT-6 cells treated with PII or TPPS and4
light can to a large extent be attributed to the modulatory effects of verapamil on endocytosis. q 1998 Elsevier Science B.V.
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1. Introduction
 .Photodynamic therapy PDT is an experimental
treatment modality which presently is undergoing
w xclinical trials 1,2 . The cytotoxic effects are sug-
gested to be mainly mediated through the formation
of singlet oxygen, oxidizing unsaturated fatty acids,
w xcholesterol, some amino acids as well as guanine 3 .
Abbreviations: b-AGA, b-N-acetyl-D-glucosaminidase; HpD,
hematoporphyrin derivative; NR, neutral red; PII, Photofrin II;
 .TPPS , tetra 4-sulfonatophenyl porphine; TPPS , meso-tetra-4 2a
phenylporphine with 2 sulfonate groups on adjacent phenyl rings
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The subcellular damage introduced by singlet oxygen
will depend on the intracellular localization of the
photosensitizer.
Calcium homeostasis has been found to be per-
turbed in cells after photochemical treatment with
w xseveral photosensitizers 4–7 . The increased intra-
cellular free Ca2q has been suggested to act as a
cytoprotective response in T24 cells through forma-
tion of prostaglandins and c-AMP, which can act as
w xmembrane stabilizing agents 8 . On the other hand,
in L929 cells attenuation of the increased free cal-
cium induced by PDT reduced the sensitivity of these
w xcells to PDT 9 . Another approach to study the
importance of calcium in the cytotoxic effects of
0005-2736r98r$19.00 q 1998 Elsevier Science B.V. All rights reserved.
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PDT is to combine PDT with calcium channel block-
w xers, like verapamil and diltiazem 10 . Biade et al.
w x10 found that these drugs potentiated the sensitivity
of HT29-18 cells to PII-induced photoinactivation. In
this study it was concluded that the sensitization
induced by the calcium channel blockers was not due
to enhanced uptake of PII which could have occurred
due to the effect of verapamil on the 170 kD MDR
w xglycoprotein or on the uptake of LDL 11–14 . To
further elucidate the mechanisms of verapamil-en-
hanced sensitization of cells treated with PDT an-
other cell line has been selected and the effect on
PII-PDT has been compared with PDT using TPPS4
as photosensitizer.
2. Materials and methods
2.1. Chemicals
 .Photofrin II PII was provided by PII Medical
 .Raritan, NJ , and TPPS by Porphyrin Products4
 .Logan, UT . Verapamil and p-nitrophenyl-N-acetyl-
b-D-glucosaminide were purchased from Sigma St.
.Louis, MO . All chemicals were of the highest purity
available.
2.2. Cell culti˝ation
w xMouse fibrosarcoma cells of the line EMT-6 15
were cultivated in HAM F-10 medium containing
10% foetal calf serum and antibiotics 50 Urml
.penicillin and 50 mgrml streptomycin . The cells
displayed a doubling time of 10–12 h and were
subcultured at least twice a week.
2.3. Labelling with photosensitizers, ˝erapamil and
irradiation
The cells were seeded out and incubated overnight
for proper attachment to the substratum. The next day
the cells were incubated with 75 mgrml TPPS or4
1.5 mgrml PII in the presence or absence of 50 mM
 .verapamil if not otherwise described for 18–20 h.
The cells were washed 3 times with 0.9% NaCl
before exposure to light. Cells treated with PII were
exposed to UVA light at a fluence rate of 2 mWrcm2
with a Vilber–Lourmat TF-35L system while cells
treated with TPPS were exposed to light using an4
 .illumination table 30=25 cm thermostated at 378C
and having two 500 W tungsten–halogen lamps
whose light was filtered through Balzers R 65 optical
 .filters 600 nm long-pass filter . The fluence rate was
7 mWrcm2. Fluence rates for both lamps were deter-
mined by chemical actinometry using the photosensi-
w xtized degradation of histidine as actinometer 16 .
Treatment with light alone at the doses given here
does not cause any reduction in cell survival.
2.4. Cellular uptake of PII and TPPS4
80=104 cells were seeded out in 20 cm2 dishes
and incubated overnight for proper attachment to the
substratum. The next day the cells were incubated
with the sensitizer as described above. At the end of
the incubation period the cells were washed 3 times
with PBS. Cells treated with TPPS were scraped off4
the substratum in 1 ml of PBS and 100 ml 1 M
NaOH were added and mixed into the solution. TPPS4
was measured spectrofluorometrically Perkin-Elmer
.LS-5 using a 1 ml cuvette and the fluorescence was
measured by exciting the samples at 420 nm and
detecting the emission at 648 nm. Cut-off filters were
 .used both on the excitation 345 nm and on the
 .emission 545 nm side to avoid contributions from
second order light. Cells treated with PII were scraped
off the substratum in 1 ml of 1% Triton X-100. PII
was measured as TPPS except that PII was excited4
at 403 nm and fluorescence detected at 629 nm. For
quantification a standard of known concentration was
added to the samples to increase the fluorescence by
50–100%. The cellular uptake studies were based on
w xestablished procedures 17,18 and the results anal-
ysed by Student’s t-test.
2.5. Cytotoxicity assay
Approximately 2000 cellsrcm2 were seeded out in
2  .10 cm dishes Nunclon and treated as described
above. Cytotoxicity was measured by the neutral red
w xassay as previously described 19,20 . A stock solu-
tion of 0.4% of neutral red was diluted 40 times in
 .HAM F-10 medium without serum the day before
 .performing the assay. The diluted neutral red NR
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solution was centrifuged before use to remove neutral
red crystals. Immediately after photodynamic treat-
ment the cells were washed twice with saline 0.9%
.NaCl and the cells were incubated with 500 ml of
the NR solution for 2 h. Subsequently, the cells were
washed twice with saline and incubated for 2 min in
500 ml 0.4% formaldehyde containing 10% CaCl .2
The formaldehyde solution was then sucked off and 1
ml of a mixture containing 50% ethanol, 20% acetic
acid and 30% H O was added. NR uptake was2
measured spectrophotometrically at 540 nm using a
Perkin-Elmer Lamda 5 spectrophotometer.
2.6. Fluorescence microscopy
2  .Ten-cm dishes Falcon 3001 were used in the
microscopical studies. The cells were washed once
with PBS and a cover glass was gently put on top of
a PBS layer. The cells were subsequently studied by
a Zeiss Axioplan microscope equipped with epifluo-
rescence. A HBOr100 W mercury lamp was used for
excitation. The cells and the cellular fluorescence
were studied by the means of a cooled charge-cou-
 . pled device CCD camera TE2, Astromed, Cam-
.bridge . A computer controlled the camera operation
and was used for digital image processing and stor-
age. The microscope was equipped with a 390–440
nm band pass excitation filter, a 470 nm dichroic
beam splitter and a 610 nm long pass filter.
( )2.7. b-N-acetyl-D-glucosaminidase b-AGA assay
Cells used for enzymatic measurements were
trypsinized, pelleted and seeded out on 10 cm2 dishes
 .  6Falcon 1008 1=10 cells in HAM F-10 medium
 ..containing 10% serum . The cells were then irradi-
ated and pelleted immediately after irradiation. b-
AGA activity was measured as described by Beaufay
w xet al. 21 . The method is based on the formation of
p-nitrophenol from the substrate p-nitrophenyl-N-
.acetyl-b-D-glucosaminide which can be registered
spectrophotometrically at 410 nm. The amount of
photosensitizer in the cells did not influence on the
w xmeasurements as also found in a previous study 22 .
2.8. LDL preparation, labeling and binding assay
LDL, taken as the 1.024–1.050 fraction, was pre-
pared from sera of healthy volunteers by sequential
w xultracentrifugation according to Havel et al. 23 .
w125 xLDL labeling was performed with I Na by the
w xmethod of Bilheimer et al. 24 . The specific radioac-
 .tivity was about 300 dpmrng. LDL binding at 48C
 .or binding and internalization at 378C were assayed
w xaccording to Goldstein and Brown 25 . To this pur-
pose, the cells were precultured for 24 h in Ham F10
medium supplemented with 2% Ultroser G and vera-
pamil when indicated, then washed 3 times with PBS,
 .and incubated either for 1 h at 48C binding or for 4
 .h at 378C binding plus internalization in the pres-
ence of 125I-LDL as indicated on the figures or figure
legends, in 0.5 ml Ham F10 medium, pH 7.4, supple-
mented with 2% Ultroser G and 25 mM Hepes
buffer, in the absence or in the presence of a large
 .excess 0.25 mgrml of unlabeled LDL. Experiments
were stopped on ice. Cells were washed 3 times with
cold PBS, then dissolved in 0.1 N NaOH. The cell-
associated radioactivity was measured using a 1275
minigamma LKB gamma counter. The specific bind-
ing or binding plus internalization was calculated as
follows: cpmrmg cell protein measured in the ab-
. sence of unlabeled LDL y cpmrmg cell protein
.measured in the presence of unlabeled LDL . The
results are expressed as ng125I-LDLrmg cell protein.
Protein determination was done by the technique of
w xPeterson 26 .
3. Results
In a previous study verapamil was found to en-
hance the PII-induced photosensitization of HT29-18
w xcells as measured by a chromate release assay 10 .
Since the influence of verapamil on the cellular
metabolism and in particular the pharmacology of PII
might be cell line dependent another cell line, the
mouse mammary tumor line EMT-6, was selected in
this study. In accordance with the results from the
HT29-18 cells 50 mM, but not 10 mM verapamil
enhanced the photosensitivity of PII-treated EMT-6
cells as measured by another cytotoxicity assay, i.e.,
 .the neutral red uptake assay Fig. 1a . Verapamil was
usually given overnight together with the photosensi-
 .tizer. Cells treated with verapamil 50 mM only 1 h
before light exposure was equally sensitive to PDT as
cells treated with PII and light only. Verapamil was
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 .  .Fig. 1. Viability of EMT-6 cells exposed to PII a or TPPS b4
 .  .  .in the absence ‘ or presence of 10 mM B or 50 mM ’
verapamil. Bars, SE from a representative experiment performed
in duplicate.
usually removed from the medium immediately be-
fore exposure to light. However, exposure of cells to
light in the presence of a medium containing vera-
pamil did not further sensitize the cells to photoinac-
Fig. 2. Cellular uptake of PII or TPPS in the absence or4
 .presence of 50 mM verapamil V as indicated on the figure. The
results are normalized to that of cells treated in the absence of
verapamil. Bars, SE from 4 independent experiments performed
in duplicate.
tivation. The cellular uptake of NR was not influ-
enced by cotreatment with 50 mM verapamil data
.not shown .
PII is a mixture of porphyrin derivatives of which
dihematoporphyrin ether or esters are suggested to be
the most efficient in sensitizing cells to photoinacti-
w xvation 27,28 . To further study the influence of
verapamil on PDT another photosensitizer, TPPS ,4
with different physico-chemical properties as well as
intracellular localization from PII, was selected. Sur-
prisingly, verapamil reduced the sensitivity of the
 .cells to TPPS -induced photoinactivation Fig. 1b .4
Verapamil has previously been shown to influence
not only the calcium homeostasis but also the uptake
w xand metabolism of LDL 11,13 . A large fraction of
PII is bound to LDL and cellular uptake is suggested
to be influenced by the presence of LDL, while
w xTPPS is practically not bound to LDL 29,30 . The4
sensitizing properties of verapamil could therefore be
due to effects on cellular uptake of the photosensitiz-
Fig. 3. Fluorescence micrographs of EMT-6 cells treated with PII
or TPPS as indicated on the figure. Cells exposed to light were4
evaluated 30 min after light exposure. The light doses reduced
the cellular viability by approximately 50%.
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Fig. 4. Relative b-AGA activity in EMT-6 cells treated with PII
 .  .‘ or TPPS B and light normalized to the dose inactivating4
 .80% of the cells D . The b-AGA activity was normalized20
against the activity in cells treated with TPPS alone. Exposure4
of cells to light alone has no effect on b-AGA activity.
ers. Cellular uptake studies showed that this was
 .indeed the case Fig. 2 . Verapamil was found to
 .enhance the uptake of PII by 30% p-0.05 , while
the uptake of TPPS was reduced by approximately4
 .20% 0.05-p-0.1 .
TPPS is in most cell lines due to endocytic4
w xuptake located in lysosomes 31 . Fluorescence mi-
 .croscopic studies Fig. 3 in combination with studies
of photochemical inactivation of the lysosomal marker
 .enzyme b-AGA Fig. 4 confirms that TPPS is4
lysosomally located in the EMT-6 cells. The granular
w125 xFig. 5. Binding of I -labeled LDL to EMT-6 cells at 48C as
described in Section 2. Symbols: ‘, total binding; B, specific
binding; ’, non specific binding. Bars, SD from 3 experiments
in duplicate.
fluorescence pattern from the cellbound TPPS re-4
w xsembles also that of lysosomes 32 . Furthermore, the
short lifetime and diffusion length of singlet oxygen,
formed by TPPS and light, in a cellular environment4
strongly indicate that inactivation of b-AGA is most
w xlikely due to lysosomally located TPPS 33 . On the4
other hand, PII is usually diffusely located extranu-
w xclearly in cells 34 or only located partly in lyso-
w xsomes 35 . However, in EMT-6 cells PII was located
granularly, resembling the localization of TPPS .4
Photochemical inactivation studies of b-AGA con-
firmed that PII was to a large extent located in
lysosomes. The apparently lower effect of photo-
chemically activated PII, than that of TPPS , on the4
inactivation of b-AGA may be due to the more
w xhydrophobic properties of PII 22 . PII may associate
to a higher extent with the lysosomal membranes
than TPPS and thus may locate more distantly from4
w xb-AGA than TPPS as was found for TPPS 36 .4 2a
Additionally, some lysosomes, named telolysosomes,
may not be involved in fusion with endosomes and
b-AGA in these vesicle cannot be photochemically
w xinactivated 37,38 . The intracellular localization of
PII and TPPS was not found to be influenced by the4
 .presence of verapamil data not shown .
The verapamil-induced increase in PII uptake might
reflect an increased uptake of LDL due to, e.g., an
increased number of LDL receptors. Thus, the bind-
Fig. 6. Repression of the LDL receptor by exogenous LDL. The
cells were cultured for 24 h in medium supplemented with
 .various concentrations up to 500 mgrml of unlabeled LDL,
then washed, and the specific LDL binding was measured as
specified in Section 2. Results are expressed as percentage of
 .controls cells cultured in the absence of LDL . Bars, SD from 3
experiments in duplicate.
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Fig. 7. Effect of verapamil on LDL binding and uptake at 378C
by EMT-6 cells. The cells were pretreated for 24 h with the
indicated concentrations of verapamil. Binding and internaliza-
w125 xtion of 10 mgrml I -labeled LDL to EMT-6 cells at 378C for
4 h was measured as described in Section 2. The results are
presented as relative to controls. Bars, SD from 3 experiments in
duplicate.
ing of the photosensitizers to the cells at 08C was
initially investigated. However, the fluorescence mea-
surements were perturbed by high unspecific binding
of the photosensitizers to the substratum introducing
unreliable results. The uptake and binding of LDL in
the EMT-6 cells were therefore characterized. The
binding of LDL to the surface of the EMT-6 cells
was found to be due to both receptor-specific binding
as well as a relatively high non-specific component
 .Fig. 5 . The expression of the LDL receptor was also
found to be feedback regulated by the extracellular
 .concentration of LDL Fig. 6 . In cells treated with
verapamil there was a progressive increase in LDL
binding and uptake with increasing concentrations of
verapamil. After overnight treatment with 50 mM
verapamil the binding and uptake of LDL was in-
 .creased by 40% Fig. 7 .
4. Discussion
The calcium antagonists are usually divided into
 .three subclasses Class I-III , based on pharmacologi-
cal activities. Verapamil, a papaverine from class I,
has been shown to act on slow calcium channels.
Additionally, verapamil seems to bind to the 170 kDa
w xmultidrug resistance related glycoprotein 39,14 , in-
w xdependent of its effect on calcium ion fluxes 40 . A
third property of verapamil is its modulatory effects
on LDL metabolism. In several cell lines verapamil
has been found to increase the binding, i.e., increase
the number of LDL receptors, and internalization of
w xLDL 11,41,13 . Degradation of LDL is often in-
creased at low concentrations of verapamil while
 .higher concentrations )50 mM may inhibit degra-
dation through a verapamil-induced increase in lyso-
w xsomal pH 11,42 . In the present study verapamil was
found to increase the sensitivity of the EMT-6 cells
 .to PII-induced photoinactivation Fig. 1 . This en-
hanced sensitivity may be attributed to an increased
 .uptake of PII Fig. 2 . PII binds to a large extent to
LDL and the uptake has been suggested to be related
w xto the uptake of LDL 43,44,30 . The enhanced bind-
ing and uptake of LDL induced by verapamil in the
 .EMT-6 cells Fig. 7 indicate thus that verapamil
stimulates LDL-mediated uptake of PII. However, the
uptake of PII was increased by only 30% while the
sensitivity of the cells to photoinactivation was in-
 .creased by a factor of 2 Figs. 1 and 2 . Other
unknown factors than total uptake may therefore also
be involved in the verapamil induced sensitization.
In a previous study verapamil was found to in-
crease the sensitivity of HT29-18 cells to treatment
w xwith Photofrin and light 10 . In this cell line the
uptake of PII was not affected by verapamil and
verapamil only slightly increased the uptake of LDL.
The verapamil-induced stimulation of the LDL path-
way seems therefore to be less effective in HT29-18
than in several other cells such as smooth muscle
w xcells, human skin fibroblasts and hepatomas 11,13 .
In HT29-18 cells verapamil may instead influence on
the calcium homeostasis which has previously been
shown to have impact on the sensitivity of the cells to
w x w xphotoinactivation 9,8 . Purkiss et al. 45 suggested
that HpD was a substrate for the MDR glycoprotein,
as revealed from studies of the effect of verapamil on
uptake and efflux of HpD by multicellular spheroids
from colorectal cell lines. In contrast, Cowled and
w xForbes 46 found no enhanced sensitization by vera-
pamil of Lewis lung carcinoma cells treated with
HpD and light. In these experiments verapamil was
applied only 1 h before PDT together with a 10-fold
higher concentration of HpD. Altogether, these re-
sults indicate that both the cell line and the experi-
mental conditions may influence on the effect of
w xverapamil in combination with PDT 47 .
TPPS is a hydrophilic dye with low or no affinity4
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w xfor lipoproteins 29 . This is in accordance with the
lack of verapamil-induced sensitization of cells treated
 .with TPPS and light Fig. 1 . Surprisingly, vera-4
pamil was found to desensitize cells treated with
 .TPPS and light Fig. 1 , most likely due to a re-4
 .duced uptake of TPPS Fig. 2 although the sensitiv-4
ity towards TPPS -PDT is reduced somewhat more4
 .than the uptake Figs. 1 and 2 . TPPS is taken up4
into cells by endocytosis and locates intracellularly in
w xendosomes and lysosomes 32,48 . There are no indi-
cations in the literature for a LDL-mediated uptake of
TPPS , and TPPS is most likely taken up by adsorp-4 4
w xtive endocytosis and pinocytosis 49 , i.e., a clathrin-
independent uptake. The present results may there-
fore indicate that verapamil attenuate the clathrin-in-
dependent pathway and stimulate clathrin-mediated
endocytosis.
PII is usually found by fluorescence microscopy to
be located diffusely in the extranuclear cytoplasm
w x34,50,51 , most likely unspecifically in membrane
w xstructures 52 . Porphyrins prebound to LDL seems to
be taken up to a higher extent by endocytosis and
localize to some extent in endosomes and lysosomes
w x53,54 . In the EMT-6 cells lysosomal localization of
PII was much clearer than seen in other cell lines as
revealed by the subcellular localization of fluorescing
 .PII Fig. 3 and by the photochemical inactivation of
 .the lysosomal marker enzyme b-AGA Fig. 4 . The
short range of action of 1O , the main cytotoxic2
product formed in PDT, indicates that inactivation of
b-AGA is due to photoactivation of lysosomally lo-
w xcated PII 33 . There are some evidence in the litera-
ture for cell type dependent uptake and localization
w xof photosensitizers 55,56 . The EMT-6 cells are of
fibrosarcoma origin and the uptake and intracellular
routing of PII in EMT-6 cells may deviate from that
in other cell types. However, although intracellular
localization of PII in other fibrosarcomas has so far
not been described fibrosarcomas does not seem to be
different from other cell types with respect to rate of
w xuptake of PII in vitro as well as in vivo 17,57 .
In summary, the present results indicate that 50
mM verapamil can potentiate the sensitivity of cells
to PII-induced photocytotoxicity. In contrast, vera-
pamil was found to attenuate the sensitivity of cells
to TPPS -induced photocytotoxicity. These effects of4
verapamil were attributed to its modulatory effect on
LDL uptake in EMT-6 cells.
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